Annalice Gandini, Fellow at Cordeliers Research Center, shared a post on LinkedIn:
“Happy to share our poster presenting real-world data on the safety and efficacy of encorafenib plus panitumumab in BRAF V600E mutated mCRC patients who experienced severe toxicity with cetuximab. ORR, PFS and OS are comparable to those reported in the BEACON trial, supporting this combination as a potential option in patients unable to continue cetuximab.”
More posts featuring Annalice Gandini.